Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer

NCT00024427 is registered in ClinicalTrials.gov with Wellstat Therapeutics as lead sponsor.

NCT NCT00024427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00024427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer
Lead sponsor
Wellstat Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2001
Completion date
Not reported
Enrollment
250 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

drug/agent toxicity by tissue/organ, pancreatic cancer